New cocktail aims to tame Slow-Growing blood cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years, regardless of sex; 2. Confirmed diagnosis of follicular lymphoma (FL), or histopathologically confirmed CD20-positive marginal zone lymphoma (MZL), including extranodal marginal zone lymphoma (MALT), splenic marginal zone lymphoma (SMZL), and nodal marginal zone lymphoma (NMZL),or confirmed diagnosis of indolent mantle cell lymphoma (MCL); 3. Patients with a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); 4. Confirmed diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia; 5. Presence of indications for treatment of indolent B-cell lymphoma; 6. No prior systemic antitumor therapy for lymphoma; 7. ECOG-PS score 0-2; 8. Essentially normal bone marrow hematopoietic function, with routine blood tests as follows: white blood cell count \>3000/uL, absolute neutrophil count ≥1.5 × 10\^9/L (use of granulocyte colony-stimulating factor is allowed), platelet count ≥75 × 10\^9/L (transfusion to reach this minimum platelet count is allowed), and hemoglobin ≥9.0 g/dL (prior red blood cell transfusion or use of recombinant human erythropoietin is allowed). If peripheral blood abnormalities are caused by lymphoma involvement of the bone marrow or spleen, neutrophils≥1.0 × 10\^9/L and platelets≥50 × 10\^9/L are acceptable (the investigator may determine at his/her discretion whether enrollment is appropriate); 9. Normal function of major organs: 1. Hepatic function: serum bilirubin ≤2.0 × ULN; serum ALT and AST ≤2.5 × ULN; 2. Renal function: creatinine clearance \>30 mL/min; 10. Expected survival≥3 months as judged by the investigator; Voluntary written informed consent signed before trial screening; Exclusion Criteria: 1. Current or prior other malignancy, unless curative treatment has been performed and there has been no evidence of recurrence or metastasis within the past 5 years; 2. Lymphoma involvement of the central nervous system or transformation to a higher-grade lymphoma; 3. Hepatic or renal dysfunction unrelated to lymphoma: alanine aminotransferase (ALT) \>3 times the upper limit of normal, aspartate aminotransferase (AST) \>3 times the upper limit of normal, total bilirubin (TBIL) \>2 times the upper limit of normal, or serum creatinine \>1.5 times the upper limit of normal; 4. Other serious medical conditions that would affect this study (e.g., uncontrolled diabetes, gastric ulcer, or other serious cardiopulmonary diseases). The investigator has the authority to make this determination; 5. Severe or uncontrolled infection; 6. Clinically manifest central nervous system dysfunction; 7. Major surgery within the past 30 days (excluding lymph node biopsy); 8. Pregnant or lactating women, or women of childbearing potential who have not used contraceptive measures; 9. Allergy to the study drug; Patients considered unsuitable for enrollment by the investigator.